NZ612295A - Novel 19-nor-steroids and their use for treating progesterone-dependent conditions - Google Patents
Novel 19-nor-steroids and their use for treating progesterone-dependent conditionsInfo
- Publication number
- NZ612295A NZ612295A NZ612295A NZ61229511A NZ612295A NZ 612295 A NZ612295 A NZ 612295A NZ 612295 A NZ612295 A NZ 612295A NZ 61229511 A NZ61229511 A NZ 61229511A NZ 612295 A NZ612295 A NZ 612295A
- Authority
- NZ
- New Zealand
- Prior art keywords
- steroids
- novel
- progesterone
- treating
- composition
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title abstract 4
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 229960003387 progesterone Drugs 0.000 title abstract 2
- 239000000186 progesterone Substances 0.000 title abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- SQWBBFUHZKCYCT-YSTOQKLRSA-N (8s,13s,14s,17s)-17-acetyl-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical class C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 SQWBBFUHZKCYCT-YSTOQKLRSA-N 0.000 abstract 1
- 208000005641 Adenomyosis Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 201000009274 endometriosis of uterus Diseases 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000006216 vaginal suppository Substances 0.000 abstract 1
- 229940120293 vaginal suppository Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/062068 WO2011119194A1 (en) | 2010-03-22 | 2010-12-23 | Compositions and methods for non-toxic delivery of antiprogestins |
| PCT/US2011/050859 WO2012087389A1 (en) | 2010-12-23 | 2011-09-08 | Novel 19-nor-steroids and their use for treating progesterone-dependent conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ612295A true NZ612295A (en) | 2014-07-25 |
Family
ID=44681424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ612295A NZ612295A (en) | 2010-12-23 | 2011-09-08 | Novel 19-nor-steroids and their use for treating progesterone-dependent conditions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130274234A1 (enExample) |
| EP (1) | EP2655394A1 (enExample) |
| JP (2) | JP2014500316A (enExample) |
| KR (1) | KR20130132955A (enExample) |
| CN (1) | CN103403017A (enExample) |
| AU (1) | AU2011345341B2 (enExample) |
| CA (1) | CA2820877A1 (enExample) |
| MX (1) | MX2013006732A (enExample) |
| NZ (1) | NZ612295A (enExample) |
| SG (1) | SG191207A1 (enExample) |
| UA (1) | UA113283C2 (enExample) |
| WO (1) | WO2012087389A1 (enExample) |
| ZA (1) | ZA201304381B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2872644A1 (en) | 2012-05-31 | 2013-12-05 | Allergan Pharmaceuticals International Limited | Formulations and methods for vaginal delivery of antiprogestins |
| US9545411B2 (en) * | 2012-11-02 | 2017-01-17 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
| US10064815B2 (en) * | 2014-05-05 | 2018-09-04 | Repros Therapeutics Inc. | Formulations and methods for vaginal delivery of antiprogestins |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| JPH0830004B2 (ja) | 1983-11-14 | 1996-03-27 | コロンビア ラボラトリーズ インコーポレイテッド | 生物接着性組成物およびそれにより治療する方法 |
| FR2573657B1 (fr) * | 1984-11-29 | 1989-05-12 | Roussel Uclaf | Produit comprenant une substance antiprogestomimetique et une substance uterotonique |
| US4954490A (en) * | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| ES2152671T3 (es) * | 1996-05-01 | 2001-02-01 | Us Gov Health & Human Serv | Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales. |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| ATE396197T1 (de) * | 2000-03-17 | 2008-06-15 | Us Gov Health & Human Serv | 17-alpha-substituierte-11-beta-substituierte-4- aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität |
| MY150763A (en) * | 2006-10-24 | 2014-02-28 | Repros Therapeutics Inc | Compositions and methods for suppressing endometrial proliferation |
| WO2009061569A1 (en) * | 2007-11-05 | 2009-05-14 | Repros Therapeutics Inc. | Compositions and methods for treating dysfunctional uterine bleeding |
| TWI539953B (zh) * | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
-
2011
- 2011-08-09 UA UAA201309244A patent/UA113283C2/uk unknown
- 2011-09-08 EP EP11761438.8A patent/EP2655394A1/en not_active Withdrawn
- 2011-09-08 KR KR1020137019568A patent/KR20130132955A/ko not_active Ceased
- 2011-09-08 CA CA2820877A patent/CA2820877A1/en not_active Abandoned
- 2011-09-08 CN CN2011800682607A patent/CN103403017A/zh active Pending
- 2011-09-08 WO PCT/US2011/050859 patent/WO2012087389A1/en not_active Ceased
- 2011-09-08 NZ NZ612295A patent/NZ612295A/en not_active IP Right Cessation
- 2011-09-08 US US13/997,097 patent/US20130274234A1/en not_active Abandoned
- 2011-09-08 SG SG2013046602A patent/SG191207A1/en unknown
- 2011-09-08 AU AU2011345341A patent/AU2011345341B2/en not_active Ceased
- 2011-09-08 JP JP2013546126A patent/JP2014500316A/ja not_active Withdrawn
- 2011-09-08 MX MX2013006732A patent/MX2013006732A/es unknown
-
2013
- 2013-06-13 ZA ZA2013/04381A patent/ZA201304381B/en unknown
-
2016
- 2016-07-08 JP JP2016135644A patent/JP2016180004A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013006732A (es) | 2013-07-17 |
| SG191207A1 (en) | 2013-07-31 |
| CA2820877A1 (en) | 2012-06-28 |
| AU2011345341B2 (en) | 2016-10-20 |
| JP2014500316A (ja) | 2014-01-09 |
| JP2016180004A (ja) | 2016-10-13 |
| UA113283C2 (xx) | 2017-01-10 |
| CN103403017A (zh) | 2013-11-20 |
| ZA201304381B (en) | 2014-03-26 |
| KR20130132955A (ko) | 2013-12-05 |
| US20130274234A1 (en) | 2013-10-17 |
| WO2012087389A1 (en) | 2012-06-28 |
| AU2011345341A1 (en) | 2013-07-04 |
| EP2655394A1 (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3732B1 (ar) | مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض | |
| WO2011009530A3 (de) | 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten | |
| WO2011009529A3 (de) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten | |
| WO2011098437A3 (de) | Progesteronrezeptorantagonisten | |
| MY161059A (en) | Progesterone antagonists such as cdb-4214 in the treatment of embodimetriosis, uterine fibroids, dysmenorrhea, breast cancer etc | |
| CU20140088A7 (es) | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina | |
| WO2011009534A3 (de) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten | |
| WO2009134725A3 (en) | Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc | |
| NZ602525A (en) | Compositions and methods for non-toxic delivery of antiprogestins | |
| CY1121190T1 (el) | Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης | |
| MA32477B1 (fr) | Derives estratrienes comprenant des bioisosteres heterocycliques pour le cycle a phenolique | |
| MX2013006732A (es) | 19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona. | |
| TW200738665A (en) | Nonsteroidal progesterone receptor modulators | |
| UY30815A1 (es) | Moduladores no esteroidales del receptor de progesterona | |
| EA200702524A1 (ru) | Нестероидные модуляторы рецептора прогестерона | |
| PH12015502318A1 (en) | Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists | |
| TN2011000022A1 (en) | Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a - ring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2016 BY COMPUTER PACKAGES INC Effective date: 20150818 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2017 BY COMPUTER PACKAGES INC Effective date: 20160818 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2018 BY COMPUTER PACKAGES INC Effective date: 20171031 |
|
| LAPS | Patent lapsed |